Table 2.
Prevalence of autoantibodies and clinical manifestations in different race and gender
| Race | Caucasian American | African-American | Latin American | ||
|---|---|---|---|---|---|
| Gender | Female | Male | Female | Male | Female |
| N | 62 | 13 | 20 | 3 | 5 |
| Age (mean±SD) | 51.1±12.1 | 58.8±10.3 | 46.1±16.5 | 56.6±6.2 | 41.8±15.4 |
| Topo I | 13%1 (8/62) | 23%2 (3/13) | 25% (5/20) | 100%1,2 (3/3) | 20% (1/5) |
| RNAP III | 18% (11/62) | 23% (3/13) | 10% (2/20) | 0% | 0% |
| Centromere | 16%3 (10/62) | 23% (3/13) | 0%3 | 0% | 40% (2/5) |
| U3RNP | 3%4 (2/62) | 0%5 | 35%4,5 (7/20) | 0% | 0% |
| Th | 11% (7/62) | 0% | 5% (1/20) | 0% | 0% |
| U1RNP | 16%6 (10/62) | 0% | 35%6,7 (7/20) | 33% (1/3) | 40% (2/5) |
| PM-Scl | 8% (5/62) | 0% | 0% | 0% | 0% |
| None of the above | 18% (11/62) | 31% (4/13) | 10% (2/20) | 0% | 0% |
| Proximal scleroderma | 50% (31/62) | 62% (8/13) | 55% (11/20) | 67% (2/3) | 60% (3/5) |
| ILD8 | 37%9 (23/62) | 46% (6/13) | 65%9 (13/20) | 67% (2/3) | 40% (2/5) |
| Renal crisis | 15% (9/62) | 8% (1/13) | 5% (1/20) | 0% (0/3) | 0% |
| Pulmonary hypertension | 15% (10/62) | 23% (3/13) | 25% (5/20) | 33% (1/3) | 0% |
ILD interstitial lung disease
1
p=0.004;
2
p=0.04;
3
p=0.11;
4
p=0.0005;
5
p=0.03;
6
p=0.11;
7
p=0.04 vs Caucasian;
8
p=0.03, Caucasian vs African-American;
9
p=0.07, ILD